Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis

Patients who are evaluated for liver diseases such as hepatitis C (HCV) are typically recommended for liver biopsy to determine the extent of disease progression. For patients who question whether less invasive testing is available, clinicians now have alternatives options to consider. Elastography and serum markers are two such diagnostic options reviewed in an editorial published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

Epidemiological studies report that approximately 150,000 individuals in the U.S. are diagnosed with each year, and nearly 20% of these cases have cirrhosis at initial presentation. Complications from cirrhosis are determined by the extent and progression of fibrosis or scaring of the liver. , however, is not a linear process, but one that fluctuates with the influences of age, sex, race, and obesity.

remains the gold standard for determining activity and stage of fibrosis. However, this procedure has inherent limitations that include risk of pain or bleeding, inaccurate staging from sampling error, and variability of biopsy interpretation. With the increase in availability of sophisticated laboratory blood testing, the use of diagnostic liver biopsy is on the decline. "The drawbacks to liver biopsy have prompted researchers to investigate alternative, noninvasive markers for determining the severity of liver disease," said Dr. Jayant Talwalkar of the Mayo Clinic in Rochester, MN and editorial co-author.

Noninvasive screening with , or indicators in the blood, can identify patients at risk for liver fibrosis. Fibrotest, an indirect serum marker panel, is the most widely used and validated serum marker panel used worldwide. A number of studies have confirmed this panel to be reliable in detecting stage 4 fibrosis (cirrhosis) in patients with chronic HCV. Additional studies are underway to analyze its viability in , alcoholic liver disease, and nonalcoholic fatty liver disease.

Imaging techniques such as ultrasound-based transient elastography (TE) and magnetic resonance elastography (MRE) are noninvasive procedures that measure liver stiffness. Prior studies have found TE to be up to 90% accurate in diagnosing cirrhosis, and 70%-80% accurate in detecting stage 2 to stage 4 fibrosis. Evaluations of MRE have shown up to 85% accuracy for detecting intermediate to severe fibrosis (F2-F4). Currently only MRE is approved for use in the U.S.

"Noninvasive diagnostics are more advantageous to the patient as there are no serious side effects and they may be more cost effective when compared to liver biopsy although this remains to be determined," Dr. Talwalkar concluded. "Fibrotest or elastography imaging are helpful to confirm cirrhosis or minimal to no fibrosis. Liver biopsy may still be necessary to determine stage of fibrosis in those patients where noninvasive techniques were indeterminate."

This study is published in Hepatology.

More information: Editorial: "Noninvasive Assessment of Liver Fibrosis." Doris Nguyen and Jayant A. Talwalkar. Hepatology; Published Online: May 25, 2011 (DOI: 10.1002/hep.24401); Print Issue Date: June 2011.

Related Stories

Noninvasive ways to assess liver disease

date Feb 02, 2008

Two new studies examine non-invasive ways to determine liver fibrosis and cirrhosis. An enhanced version of the Original European Liver Fibrosis panel was found to have good diagnostic accuracy for fibrosis in patients with ...

Noninvasive tests for cirrhosis may help to avoid liver biopsy

date Oct 01, 2007

Newer ultrasound and magnetic resonance (MR) imaging tests yield encouraging initial results in diagnosing fibrosis (scarring) and cirrhosis of the liver, according to three studies in the October issue of the journal Clinical Ga ...

Recommended for you

Score IDs patients with upper extremity DVT at low risk

date 11 hours ago

(HealthDay)—For patients with upper-extremity deep vein thrombosis (DVT), six easily available factors can be used to create a score that identifies those at low risk of adverse events during the first ...

Combined drug treatment combats kidney disease

date 21 hours ago

A recent discovery by drug researchers whereby coupling specific cell membrane receptors has altered kidney cell function has triggered a re-think of how to treat chronic kidney disease (CKD) more effectively.

Active substance targeting dreaded hospital germs

date 21 hours ago

In the German Center for Infection Research (DZIF), scientists have conducted clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: a highly effective protein from bacteriophages ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.